It's interesting to note news regarding Biotech Capital, the life science investment group, who hold 29.1m shares in Phylogica. According to Biotechnologynews.net;
"Biotech Capital has changed its investment strategy and will cash out its investments to shareholders within 18 months."
Is this significant in regards to Phylogica's own investment objective to achieve a trade sale? I note that Harry Karelis is on the Board of both Biotech and Phylogica. There is no answer of course only guesswork but in the words of Banjo Patterson 'there is movement at the station.'
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.36 |
Change
0.005(0.37%) |
Mkt cap ! $793.2M | |||
| Open | High | Low | Value | Volume |
| $1.40 | $1.40 | $1.36 | $211.9K | 152.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 4103 | $1.36 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.39 | 2028 | 1 |
View Market Depth
| Last trade - 16.10pm 18/07/2025 (20 minute delay) ? |
| PYC (ASX) Chart |